Champions Oncology (CSBR) Short-Term Debt to Equity

Champions Oncology (CSBR) business relies on the value of live tumor samples, although biotech cost-cutting is limiting price growth, with the current metric standing at 0.52. Diplomatic disputes are hindering the cross-border movement of bio-models, which is stalling global deals with pharma behemoths. This chart of the asset's market valuation below demonstrates a dependence on the demand for clinical tests and the size of the PDX-model base for therapy forecasting.

This ratio determines the share of liabilities maturing within one year in the overall capital structure, reflecting the level of operational liquidity and the business's dependence on rapid refinancing. By analyzing the trend of short-term debt to equity, an investor assesses the ability of Champions Oncology (CSBR) to sustain costly tumor model research without the risk of a sudden cash shortfall.